What is driving new furazolidone capacity when the product is banned in food animals?

What is driving new furazolidone capacity when the product is banned in food animals?
Recent project disclosures show furazolidone still appearing in new and expanded pharmaceutical intermediate builds, typically at modest scale such as one tonne per year alongside other APIs. That tells you the remaining legitimate demand is narrow and specialty-oriented rather than commodity-scale. The molecule also sits within a broader nitrofuran chemistry family that shares nitration routes, so producers often retain the capability for adjacent products. Meanwhile, nitration itself is under pressure: conventional mixed-acid processes carry thermal runaway risk and generate nitrogen oxide and acid waste, pushing interest toward catalytic and biocatalytic alternatives that cut energy use substantially. For furazolidone specifically, capacity decisions will hinge on regulatory risk and route economics rather than volume growth.